Why PepGen Inc.’s (PEPG) Stock Is Down 5.74%
As of Wednesday, July 29, PepGen Inc.’s PEPG share price has dipped by 5.74%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Commentary & Analysis
Why PepGen Inc.’s (PEPG) Stock Is Down 7.78%
As of Wednesday, July 22, PepGen Inc.’s PEPG share price has dipped by 7.78%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why PepGen Inc.’s (PEPG) Stock Is Down 6.04%
As of Thursday, July 16, PepGen Inc.’s PEPG share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why PepGen Inc.’s (PEPG) Stock Is Down 6.35%
As of Wednesday, July 15, PepGen Inc.’s PEPG share price has dipped by 6.35%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why PepGen Inc.’s (PEPG) Stock Is Up 6.56%
As of Tuesday, July 14, PepGen Inc.’s PEPG share price has surged by 6.56%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | PEPG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $121.7 | $251.9 | 23% |
|
| Shares Out (Mil) | 69.1 | 50.8 | 55% |
|
| Institutional Ownership | 99.5% | 92.0% | 89% |
|
| Float (Mil) | 36.0 | 40.5 | 40% |
|
| Beta | 1.93 | 0.95 | 91% |
|
| Avg Daily Volume (000s) | 688 | 447 | 64% |
|
| Price Change (52-week) |
27.5% | 54.2% | 67% |
|
| Growth | PEPG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | (116.2%) | (9.8%) | 1% |
|
| EPS (5yr) | 14.7% | 16.3% | 55 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (48.6%) | (15.6%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.289) | ($1.136) | ($1.230) | |
| Month Ago EPS | ($0.289) | ($1.136) | ($1.230) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.295) | ($1.165) | ($1.164) | |
| Year/Year Chg | 12.5% | (46.5%) | (48.0%) | |
| Financials | PEPG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($77) | ($43) | 13% |
|
| EPS (TTM) | ($1.504) | ($1.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($77) | ($30) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $3 | 39% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $5 | 30% |
|
| Enterprise Value (Q1) (Mil) | $8 | $182 | 7% |
|
| Valuation | PEPG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.91 | 2.60 | 20% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | PEPG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (54.4%) | (49.7%) | 11% |
|
| ROE | (68.4%) | (55.4%) | 13% |
|
| Liabilities to Assets | 14.3% | 30.3% | 9% |
|
| F-Score | 3 | 3 | 19% |
|
PepGen Inc. did not pass any screens on 7/30/2026.
